Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 413 across all filing types
Latest filing 2026-03-06 Report Publication Anno…
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
2026 General Shareholders Meeting - Notice preparatory documents
Report Publication Announcement Classification · 95% confidence The document is a short notice (approx. 2000 characters) informing shareholders about the upcoming Ordinary and Extraordinary Shareholders' Meeting, the publication of the notice of meeting in the BALO, and where to access preparatory documents. It does not contain the actual proxy materials or the meeting presentation itself, but rather serves as an announcement regarding the availability of these documents. Therefore, it falls under the 'Report Publication Announcement' category.
2026-03-06 English
AG 2026 - Avis de mise à disposition des documents préparatoires
Report Publication Announcement Classification · 95% confidence The document is a short notice (Avis de mise à disposition) informing shareholders about the availability of documents for the upcoming Annual General Meeting (Assemblée générale mixte) on May 28, 2026. It does not contain the actual meeting presentations or the full financial reports themselves, but rather announces where and when these documents will be made available. Following the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2026-03-06 French
Février 2026 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Regulatory Filings Classification · 95% confidence The document is a monthly disclosure of the total number of voting rights and shares, as required by Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. This type of regulatory disclosure regarding share capital and voting rights does not fit into specific categories like 'Share Issue' or 'Major Shareholding' and is best classified as a general regulatory filing.
2026-03-02 French
bioMérieux – Résultats annuels au 31 décembre 2025
Interim / Quarterly Report Classification · 95% confidence The document is a comprehensive financial report for bioMérieux covering the full fiscal year ending December 31, 2025. It includes detailed financial statements, consolidated income statements, revenue analysis by application and region, and management's discussion of performance, strategy (GO+28), and outlook. It is not a short announcement or a certification, but the substantive financial report itself, fitting the definition of an Interim/Quarterly Report (which covers periods shorter than a full fiscal year, but in this context, it serves as the primary annual financial disclosure document). Given the options, 'IR' is the most appropriate category for a detailed financial performance report of this nature. FY 2025
2026-02-27 French
bioMérieux – 2025 Financial Results
Earnings Release Classification · 100% confidence The document is a detailed financial press release from bioMérieux reporting their 2025 full-year financial results. It includes key performance indicators, sales breakdowns by region and application, consolidated income statements, and management commentary on the GO·28 strategic plan. While it contains financial data, it is structured as an initial announcement of results (Earnings Release) rather than a full 10-K or audited Annual Report. It provides highlights, guidance, and management's perspective on the period's performance. FY 2025
2026-02-27 English
bioMérieux lance SMARTBIOME™ pour aider les industriels de l’agroalimentaire à mieux comprendre les altérations et protéger la qualité des produits
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new product, 'SMARTBIOME™', by bioMérieux. It describes the product's features, its benefits for the food industry, and includes quotes from company executives. It does not contain financial statements, regulatory filings, or meeting notices. As it is a general corporate announcement regarding a product launch that does not fit into specific categories like M&A or management changes, it is classified as a general regulatory filing/announcement.
2026-02-18 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.